NXDC is a privately owned life science company dedicated to the commercial launch of Gliolan® in the United States as a real time imaging agent allowing surgeons to visualize brain tumors during surgery.
To bring Gliolan® to the surgical community to enhance the upfront management of patients with glioblastoma. The use of Gliolan® to visualize structural elements related to tumor presentation and enable the surgeon to make real time decisions about tumor de-bulking has become a standard in other countries and is envisioned to be well received in the US at time of commercial launch.
What We've Achieved
The company is currently planning to submit a New Drug Application to the FDA H2 2016 and is currently working with advisers and key surgeons to ensure fast track approval and commercial launch.